5i96 - Revision history

OCA at 08:27, 23 August 2023

2023-08-23T08:27:22Z

←Older revision		Revision as of 08:27, 23 August 2023
Line 3:		Line 3:
	<StructureSection load='5i96' size='340' side='right'caption='[[5i96]], [[Resolution\|resolution]] 1.55Å' scene=''>		<StructureSection load='5i96' size='340' side='right'caption='[[5i96]], [[Resolution\|resolution]] 1.55Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5i96]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5I96 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=5I96 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5i96]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5I96 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5I96 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=69Q:2-METHYL-1-[(4-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-6-{[2-(TRIFLUOROMETHYL)PYRIDIN-4-YL]AMINO}-1,3,5-TRIAZIN-2-YL)AMINO]PROPAN-2-OL'>69Q</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NDP:NADPH+DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NDP</scene~~></td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.55Å</td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5i95\|5i95]]</td></tr>~~	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=69Q:2-METHYL-1-[(4-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-6-{[2-(TRIFLUOROMETHYL)PYRIDIN-4-YL]AMINO}-1,3,5-TRIAZIN-2-YL)AMINO]PROPAN-2-OL'>69Q</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NDP:NADPH+DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NDP</scene></td></tr>
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Isocitrate_dehydrogenase_(NADP(+)) Isocitrate dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.42 1.1.1.42] </span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5i96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5i96 OCA], [https://pdbe.org/5i96 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5i96 RCSB], [https://www.ebi.ac.uk/pdbsum/5i96 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5i96 ProSAT]</span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=5i96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5i96 OCA], [~~http~~://pdbe.org/5i96 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5i96 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5i96 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5i96 ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/IDHP_HUMAN IDHP_HUMAN]] D-2-hydroxyglutaric aciduria. Defects in IDH2 are the cause of D-2-hydroxyglutaric aciduria type 2 (D2HGA2) [MIM:[~~http~~://omim.org/entry/613657 613657]]. D2HGA2 is a neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine.<ref>PMID:20847235</ref>	+	[https://www.uniprot.org/uniprot/IDHP_HUMAN IDHP_HUMAN] D-2-hydroxyglutaric aciduria. Defects in IDH2 are the cause of D-2-hydroxyglutaric aciduria type 2 (D2HGA2) [MIM:[https://omim.org/entry/613657 613657]. D2HGA2 is a neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine.<ref>PMID:20847235</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/IDHP_HUMAN IDHP_HUMAN]] Plays a role in intermediary metabolism and energy production. It may tightly associate or interact with the pyruvate dehydrogenase complex.	+	[https://www.uniprot.org/uniprot/IDHP_HUMAN IDHP_HUMAN] Plays a role in intermediary metabolism and energy production. It may tightly associate or interact with the pyruvate dehydrogenase complex.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 29:		Line 28:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: DeLaBarre, B]]	+	[[Category: DeLaBarre B]]
-	[[Category: Jiang, F]]	+	[[Category: Jiang F]]
-	[[Category: Jin, L]]	+	[[Category: Jin L]]
-	[[Category: Padyana~~, A K~~]]	+	[[Category: Padyana AK]]
-	[[Category: Travins~~, J A~~]]	+	[[Category: Travins JA]]
-	[[Category: Wei, W]]	+	[[Category: Wei W]]
-	[[Category: Zhang, B]]	+	[[Category: Zhang B]]
-	~~[[Category: Ag-221]]~~	+
-	~~[[Category: Enasidenib]]~~	+
-	~~[[Category: Icd-m]]~~	+
-	~~[[Category: Idh]]~~	+
-	~~[[Category: Idh2]]~~	+
-	~~[[Category: Idh2 ag-221]]~~	+
-	~~[[Category: Oxidoreductase-oxidoreductase inhibitor complex~~]]	+

OCA at 07:09, 3 June 2020

2020-06-03T07:09:10Z

←Older revision		Revision as of 07:09, 3 June 2020
Line 1:		Line 1:

	==Crystal Structure of Human Mitochondrial Isocitrate Dehydrogenase (IDH2) R140Q Mutant Homodimer in Complex with AG-221 (Enasidenib) Inhibitor.==		==Crystal Structure of Human Mitochondrial Isocitrate Dehydrogenase (IDH2) R140Q Mutant Homodimer in Complex with AG-221 (Enasidenib) Inhibitor.==
-	<StructureSection load='5i96' size='340' side='right' caption='[[5i96]], [[Resolution\|resolution]] 1.55Å' scene=''>	+	<StructureSection load='5i96' size='340' side='right'caption='[[5i96]], [[Resolution\|resolution]] 1.55Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5i96]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5I96 OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5I96 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5i96]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5I96 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5I96 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=69Q:2-METHYL-1-[(4-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-6-{[2-(TRIFLUOROMETHYL)PYRIDIN-4-YL]AMINO}-1,3,5-TRIAZIN-2-YL)AMINO]PROPAN-2-OL'>69Q</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NDP:NADPH+DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NDP</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=69Q:2-METHYL-1-[(4-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-6-{[2-(TRIFLUOROMETHYL)PYRIDIN-4-YL]AMINO}-1,3,5-TRIAZIN-2-YL)AMINO]PROPAN-2-OL'>69Q</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NDP:NADPH+DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NDP</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5i95\|5i95]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5i95\|5i95]]</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Isocitrate_dehydrogenase_(NADP(+)) Isocitrate dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.42 1.1.1.42] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Isocitrate_dehydrogenase_(NADP(+)) Isocitrate dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.42 1.1.1.42] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5i96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5i96 OCA], [http://pdbe.org/5i96 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5i96 RCSB], [http://www.ebi.ac.uk/pdbsum/5i96 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5i96 ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5i96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5i96 OCA], [http://pdbe.org/5i96 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5i96 RCSB], [http://www.ebi.ac.uk/pdbsum/5i96 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5i96 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 22:		Line 22:
	</div>		</div>
	<div class="pdbe-citations 5i96" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5i96" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Isocitrate dehydrogenase 3D structures\|Isocitrate dehydrogenase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: DeLaBarre, B]]		[[Category: DeLaBarre, B]]
	[[Category: Jiang, F]]		[[Category: Jiang, F]]

OCA at 17:36, 15 November 2017

2017-11-15T17:36:34Z

←Older revision		Revision as of 17:36, 15 November 2017
Line 22:		Line 22:
	</div>		</div>
	<div class="pdbe-citations 5i96" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5i96" style="background-color:#fffaf0;"></div>
-
-	==See Also==
-	*[[Isocitrate dehydrogenase\|Isocitrate dehydrogenase]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 04:46, 21 September 2017

2017-09-21T04:46:23Z

←Older revision		Revision as of 04:46, 21 September 2017
Line 22:		Line 22:
	</div>		</div>
	<div class="pdbe-citations 5i96" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5i96" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Isocitrate dehydrogenase\|Isocitrate dehydrogenase]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 16:49, 9 March 2017

2017-03-09T16:49:25Z

←Older revision		Revision as of 16:49, 9 March 2017
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5i96 is ~~ON HOLD~~ ~~until Paper~~ Publication	+	==Crystal Structure of Human Mitochondrial Isocitrate Dehydrogenase (IDH2) R140Q Mutant Homodimer in Complex with AG-221 (Enasidenib) Inhibitor.==
		+	<StructureSection load='5i96' size='340' side='right' caption='[[5i96]], [[Resolution\|resolution]] 1.55Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5i96]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5I96 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5I96 FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=69Q:2-METHYL-1-[(4-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-6-{[2-(TRIFLUOROMETHYL)PYRIDIN-4-YL]AMINO}-1,3,5-TRIAZIN-2-YL)AMINO]PROPAN-2-OL'>69Q</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NDP:NADPH+DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NDP</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5i95\|5i95]]</td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Isocitrate_dehydrogenase_(NADP(+)) Isocitrate dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.42 1.1.1.42] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5i96 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5i96 OCA], [http://pdbe.org/5i96 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5i96 RCSB], [http://www.ebi.ac.uk/pdbsum/5i96 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5i96 ProSAT]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/IDHP_HUMAN IDHP_HUMAN]] D-2-hydroxyglutaric aciduria. Defects in IDH2 are the cause of D-2-hydroxyglutaric aciduria type 2 (D2HGA2) [MIM:[http://omim.org/entry/613657 613657]]. D2HGA2 is a neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine.<ref>PMID:20847235</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/IDHP_HUMAN IDHP_HUMAN]] Plays a role in intermediary metabolism and energy production. It may tightly associate or interact with the pyruvate dehydrogenase complex.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Somatic gain-of-function mutations in isocitrate dehydrogenase (IDH) 1 and 2 are found in multiple hematologic and solid tumors, leading to accumulation of the oncometabolite, (R)-2-hydroxyglutarate (2HG). 2HG competitively inhibits alpha-ketoglutarate-dependent dioxygenases, including histone demethylases and methylcytosine dioxygenases of the Tet family, causing epigenetic dysregulation and a block in cellular differentiation. In vitro studies have provided proof of concept for mutant IDH inhibition as a therapeutic approach. We report the discovery and characterization of AG-221, an orally available, selective, potent inhibitor of the mutant IDH2 enzyme. AG-221 suppressed 2HG production and induced cellular differentiation in primary human IDH2 mutation-positive acute myeloid leukemia (AML) cells ex vivo and in xenograft mouse models. AG-221 also provided a statistically significant survival benefit in an aggressive IDH2R140Q-mutant AML xenograft mouse model. These findings supported initiation of the ongoing clinical trials of AG-221 in patients with IDH2 mutation-positive advanced hematologic malignancies.

-	~~Authors~~:	+	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.,Yen K, Travins J, Wang F, David MD, Artin E, Straley K, Padyana A, Gross S, DeLaBarre B, Tobin E, Chen Y, Nagaraja R, Choe S, Jin L, Konteatis Z, Cianchetta G, Saunders JO, Salituro FG, Quivoron C, Opolon P, Bawa O, Saada V, Paci A, Broutin S, Bernard OA, de Botton S, Marteyn BS, Pilichowska M, Xu Y, Fang C, Jiang F, Wei W, Jin S, Silverman L, Liu W, Yang H, Dang L, Dorsch M, Penard-Lacronique V, Biller SA, Su SM Cancer Discov. 2017 Feb 13. pii: CD-16-1034. doi: 10.1158/2159-8290.CD-16-1034. PMID:28193778<ref>PMID:28193778</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
		+	<div class="pdbe-citations 5i96" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: DeLaBarre, B]]
		+	[[Category: Jiang, F]]
		+	[[Category: Jin, L]]
		+	[[Category: Padyana, A K]]
		+	[[Category: Travins, J A]]
		+	[[Category: Wei, W]]
		+	[[Category: Zhang, B]]
		+	[[Category: Ag-221]]
		+	[[Category: Enasidenib]]
		+	[[Category: Icd-m]]
		+	[[Category: Idh]]
		+	[[Category: Idh2]]
		+	[[Category: Idh2 ag-221]]
		+	[[Category: Oxidoreductase-oxidoreductase inhibitor complex]]

OCA at 14:15, 15 May 2016

2016-05-15T14:15:08Z

←Older revision		Revision as of 14:15, 15 May 2016
Line 3:		Line 3:
	The entry 5i96 is ON HOLD until Paper Publication		The entry 5i96 is ON HOLD until Paper Publication

-	Authors: ~~Zhang, B., Jin, L., Wei, W., Jiang, F., DeLaBarre, B., Travins, J.A., Padyana, A.K.~~	+	Authors:

	Description:		Description:
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
-	[[Category: Zhang, B]]
-	[[Category: Jiang, F]]
-	[[Category: Travins, J.A]]
-	[[Category: Jin, L]]
-	[[Category: Wei, W]]
-	[[Category: Delabarre, B]]
-	[[Category: Padyana, A.K]]

OCA at 00:18, 11 May 2016

2016-05-11T00:18:20Z

←Older revision		Revision as of 00:18, 11 May 2016
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5i96 is ON HOLD	+	The entry 5i96 is ON HOLD until Paper Publication

	Authors: Zhang, B., Jin, L., Wei, W., Jiang, F., DeLaBarre, B., Travins, J.A., Padyana, A.K.		Authors: Zhang, B., Jin, L., Wei, W., Jiang, F., DeLaBarre, B., Travins, J.A., Padyana, A.K.

OCA: Protected "5i96" [edit=sysop:move=sysop]

2016-03-02T13:33:27Z

Protected "5i96" [edit=sysop:move=sysop]

←Older revision

Revision as of 13:33, 2 March 2016

OCA: New page: '''Unreleased structure''' The entry 5i96 is ON HOLD Authors: Zhang, B., Jin, L., Wei, W., Jiang, F., DeLaBarre, B., Travins, J.A., Padyana, A.K. Description: [[Category: Unreleased S...

2016-03-02T13:33:25Z

New page: '''Unreleased structure''' The entry 5i96 is ON HOLD Authors: Zhang, B., Jin, L., Wei, W., Jiang, F., DeLaBarre, B., Travins, J.A., Padyana, A.K. Description: [[Category: Unreleased S...

New page

'''Unreleased structure'''

The entry 5i96 is ON HOLD

Authors: Zhang, B., Jin, L., Wei, W., Jiang, F., DeLaBarre, B., Travins, J.A., Padyana, A.K.

Description:
[[Category: Unreleased Structures]]
[[Category: Zhang, B]]
[[Category: Jiang, F]]
[[Category: Travins, J.A]]
[[Category: Jin, L]]
[[Category: Wei, W]]
[[Category: Delabarre, B]]
[[Category: Padyana, A.K]]